Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons - Takeaways - MDSpire

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

  • By

  • Naseema Gangat

  • Ayalew Tefferi

  • May 7, 2025

  • 0 min

Share

  • 1

    Momelotinib is a JAK1/2 and ACVR1/ALK2 inhibitor that effectively reduces splenomegaly and alleviates anemia in myelofibrosis patients.

  • 2

    Clinical trials and real-world studies demonstrate momelotinib's consistent benefits in treating anemia, regardless of prior JAK inhibitor exposure.

  • 3

    In the MOMGEFIN study, anemia response rates were higher in JAKi-exposed patients compared to JAKi-naïve patients receiving momelotinib.

  • 4

    Common adverse events associated with momelotinib include thrombocytopenia, diarrhea, infections, and hepatotoxicity, with most being mild.

  • 5

    Momelotinib shows superior erythropoietic activity compared to other JAK inhibitors, making it a valuable option for myelofibrosis treatment.

Original Source(s)

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

  • by Naseema Gangat, Ayalew Tefferi

  • May 7, 2025

Related Content

Assessment of Clinical Complications and Treatment Approaches in Non-Transfusion-Dependent α- and β-Thalassemia Patients Compared to Matched Controls: A Retrospective Analysis Utilizing Administrative Claims Data in the United States

Smoldering Waldenström macroglobulinemia coexisting with myelodysplastic syndrome: a rare case report and literature review

Surgical Intervention for Emphysematous Osteomyelitis of the Spine in a Patient with Malnutrition and Anemia: A Unique Case Study